The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.

doi:10.1186/s12967-023-04595-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.

Journal of translational medicine - 16 Oct 2023

Giacomini Patrizio, Valenti Fabio, Allegretti Matteo, Pallocca Matteo, De Nicola Francesca, Ciuffreda Ludovica, Fanciulli Maurizio, Scalera Stefano, Buglioni Simonetta, Melucci Elisa, Casini Beatrice, Carosi Mariantonia, Pescarmona Edoardo, Giordani Elena, Sperati Francesca, Jannitti Nicoletta, Betti Martina, Maugeri-Saccà Marcello, Cecere Fabiana Letizia, Villani Veronica, Pace Andrea, Appetecchia Marialuisa, Vici Patrizia, Savarese Antonella, Krasniqi Eriseld, Ferraresi Virginia, Russillo Michelangelo, Fabi Alessandra, Landi Lorenza, Minuti Gabriele, Cappuzzo Federico, Zeuli Massimo, Ciliberto Gennaro

Abstract excerpt

BACKGROUND: Molecular Tumor Boards (MTB) operating in real-world have generated limited consensus on good practices for accrual, actionable alteration mapping, and outcome metrics. These topics are addressed herein in 124 MTB patients, all real-world accrued at progression, and lacking approved therapy options. METHODS: Actionable genomic alterations identified by tumor DNA (tDNA) and circulating tumor DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to DNA, Neoplasm

Share to High-Throughput Nucleotide Sequencing

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Neoplasms

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 37845764
DOI: 10.1186/s12967-023-04595-5
PMCID: PMC10577953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.PMID 37845764Read ↗

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read ↗

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.Semantic proximity Read ↗

The molecular tumor board—a key element of precision oncologySemantic proximity Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan.Semantic proximity Read ↗

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical CenterSemantic proximity Read ↗

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.Semantic proximity Read ↗

Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.Semantic proximity Read ↗

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University ExperienceSemantic proximity Read ↗

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicineSemantic proximity Read ↗

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read ↗

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational ProfilesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.